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Abstract. In the present study, we evaluated the diagnosis and 
management modalities of caesarean scar pregnancy (CSP). 
Thirty patients diagnosed with CSP were retrospectively 
studied between February, 2010 and February, 2012. 
Twenty-five patients were offered prophylactic uterine artery 
embolization (UAE) and methotrexate (MTX) prior to 
uterine suction curettage. Five cases were referred from other 
hospitals where the initial management with uterine suction 
curettage had resulted in uncontrollable massive haemor-
rhage, 4 of the cases had UAE and one proceeded immediately 
to hysterectomy. In the 25 patients treated with prophylactic 
UAE and MTX, 12 had laparoscopy-guided curettage and 13 
had ultrasound-guided curettage without complication. The 
results showed that the 25 patients with CSP, who received 
prophylactic UAE and MTX prior to uterine curettage, recov-
ered without complications. Five patients referred from other 
hospitals, where uterine curettage was the primary procedure, 
had severe complications including uncontrolled vaginal 
bleeding and uterine rupture. Four of the five patients were 
treated successfully with emergency UAE and the remaining 
patient underwent emergency hysterectomy as ultrasound 
examination detected significant haemorrhage between 
the uterus and the bladder. Of the 25 patients who received 
prophylactic UAE combined with MTX, there were no reports 
of irregular menstruation or serious adverse effects. Notably, 
the decrease in serum human chorionic gonadotropin (HCG) 
levels 3 days post-surgery was greater with ultrasound-guided 
curettage (84.3±5.5%) than with laparoscopy-guided curet-
tage (76.3±10.2%). In summary, the data suggested that 
prophylactic UAE with MTX followed by ultrasound-guided 
curettage is the most effective therapeutic approach in CSP.
Introduction
Caesarean scar pregnancy (CSP) is an uncommon but serious 
complication of a previous caesarean. The first case of CSP 
was reported in the medical literature in 1978 by Larsen 
and Solomon (1) and the reported incidence of CSP was 
approximately 0.15% of ectopic pregnancies (2). Since 2000, 
the incidence of CSP has increased significantly to 6.1% of all 
ectopic pregnancies in those with previous caesarean sections, 
which may reflect the increasing number of caesarean sections 
being performed and the improved accuracy of diagnosis 
of ectopic pregnancies using colour Doppler transvaginal 
ultrasono graphy (3). In addition, the rates of CSP may have 
increased as a result of the use of assisted reproduction 
techno logy (4). Typically the diagnosis was made at between 
6 and 9 weeks gestation.
CSP was confirmed by a thorough medical history evalu-
ation, including obstetric, reproductive and surgical history, a 
physical examination and increased levels of progesterone and 
total serum human chorionic gonadotropin (HCG) between 
6 and 9 weeks of gestation. The diagnosis of CSP was mainly 
accomplished by combining transvaginal sonography (TVS) 
with Doppler flow imaging (5).
There is no standard treatment for the management of 
CSP and only a few cases have been reported in the literature. 
Although CSP is rare, without a high index of suspicion and 
early diagnosis, it may result in serious maternal morbidity, 
including uterine rupture and haemorrhage, or mortality (6). 
Termination of pregnancy in the first trimester is strongly 
recommended to prevent life-threatening complications 
and to maintain the possibility of future pregnancies (7). 
In the past, the preferred treatment option was to perform a 
laparotomy with the possible need for hysterectomy to avoid 
potential lethal haemorrhage (8). The current methods for 
the management of CSP include systemic chemotherapy with 
methotrexate (MTX), local injection of embryocidic agents, 
uterine curettage, hysteroscopic evacuation, laparoscopic 
management, excision of the involved lower segment of the 
uterus, uterine artery embolization (UAE) and expectant 
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management (9,10). In the present study, we reported the 
outcome of 30 cases of CSP managed by using uterine curet-
tage as a primary approach or combined with prophylactic 
UAE and MTX prior to uterine curettage. In the 25 cases 
managed with prophylactic UAE and MTX, we compared 
CSP removal using ultrasound-guided uterine curettage and 
laparoscopy-guided curettage.
Patients and methods
Patients. Thirty patients with CSP were treated with uterine 
curettage with or without prophylactic UAE and MTX. 
These cases were identified from the Beijing Obstetrics and 
Gynaecology Hospital database and were analysed retro-
spectively. The characteristics of the 30 patients are shown 
in Table I. Clinical data were analyzed with respect to age, 
gravidity and parity, history of caesarean delivery, interval 
from the most recent caesarean delivery to diagnosis, clinical 
presentation, results of laboratory examination, process of 
diagnosis and treatment sequence, and outcome, which were 
collected from the original hospital charts, operation notes and 
outpatient medical records via telephone questionnaires.
At Beijing Obstetrics and Gynaecology Hospital, transab-
dominal ultrasound with full bladder was performed initially 
to assess the pelvis and uterus with careful inspection of the 
interface between the anterior lower uterine segment and 
bladder. This was followed by a transvaginal ultrasound to 
allow for the fine-detail evaluation of the gestational sac in rela-
tion to the scar. The diagnosis of CSP in the first trimester was 
determined based on the following ultrasonographic criteria: 
i) an empty uterus with a clearly visualized endometrium; ii) an 
empty cervical canal; iii) an anteriorly located gestational sac 
with a decreased myometrium layer between the bladder and 
the sac; and iv) a reduced or absent myometrium between the 
gestational sac and bladder on a sagittal view of the uterus (this 
was observed to be <5 mm in two-thirds of cases) (11) (Fig. 1).
Written informed consent was obtained prior to UAE 
from each participant with CSP. Approval for the study was 
obtained from the ethics committee of the Beijing Obstetrics 
and Gynaecology Hospital.
Procedure. Twenty-five patients with a clear diagnosis of CSP 
were offered prophylactic UAE prior to uterine curettage. A 
right transfemoral approach was used for artery access, and 
each uterine artery was selectively catheterized with a 4- or 
5-F Roberts uterine catheter. Prior to UAE, 50 mg of MTX 
was dissolved in 20 ml of physiologic saline solution. This 
dose was separated between the two uterine arteries and 
infused via the arterial catheter. UAE was performed by an 
experienced radiologist with the use of gelfoam particles 
(500-1,000 µm in diameter) mixed with nonionic contrast 
medium. Angiography was performed after UAE to confirm 
that the bilateral uterine arteries were occluded (Fig. 2). After 
24-48 h, uterine curettage was performed under ultrasound-
guided or laparoscopy-guided curettage to confirm the 
complete removal or destruction of the CSP mass. The other 
five patients, who were misdiagnosed from other hospitals as 
having an intrauterine pregnancy were treated with emergency 
UAE because of uncontrollable massive haemorrhage within 
48 h after uterine curettage. Prophylactic anti-infection drugs 
were administered to prevent infection. Serum HCG levels 
were measured every three days.
Follow-up. The patients were recommended to use contracep-
tion for the first year postoperatively. They were followed up 
Table I. Characteristics of the clinical cases.
  No. of previous  Interval time from recent
Values Age (years) caesarean sections No. of pregnancies caesarean section (years) Gestation (weeks)
Mean 32.20±4.83 1.20±0.61 3.60±1.55 4.45±1.34 8.34±3.70
Range (min - max) 23-43 1-4 2-7 6 months-12 years 5-12
Figure 1. Two examples of echo-images of CSP. Images were captured 
from a 30-year-old woman at 6 weeks of CSP with a history of one cae-
sarean delivery. (A) TAS showing the midline of the uterus. (B) Transverse 
TVS showing the midline of the uterus. Arrow shows pregnant scar. 
CSP, caesarean scar pregnancy; TAS, transabdominal sonography; 
TVS, transvaginal sonography.
  A
  B
EXPERIMENTAL AND THERAPEUTIC MEDICINE  12:  1469-1475,  2016 1471
by telephone interview between three months and one year 
depending on serum HCG results, ultrasonographic findings 
and menstrual cycle recovery.
Statistical analysis. Statistical analysis was undertaken using 
SPSS version 13.0 software (Chicago, IL, USA). Measurement 
data were presented as the means and standard deviations. 
The significance of between-group differences was tested 
using analysis of variance or Chi-square tests. P<0.05 was 
considered statistically significant. The data were normally 
distributed (P>0.05).
Results
Patients. A total of 30 women were included in the current 
study. Clinical presentation was described as follows: mild 
vaginal bleeding (11 patients); mild abdominal pain (1 patient); 
both of the above present (5 patients) and asymptomatic 
(8 patients; Table II). Twenty-five patients diagnosed for CSP 
by abdominal and TVS were approached to participate in 
the study. The patients received prophylactic UAE combined 
with MTX followed by uterine curettage and all 25 patients 
recovered without complications. The remaining five patients, 
who were misdiagnosed as having an intrauterine pregnancy 
in another hospital, were treated with suction curettage 
initially complicated by uncontrolled vaginal bleeding. Four 
of the five patients were treated successfully with UAE in 
our hospital. Five days after UAE, the patients underwent 
ultrasound-guided repeat uterine curettage because of a slow 
decrease in serum β-HCG or continued vaginal bleeding. The 
last patient underwent laparotomy and hysterectomy after an 
expanding haematoma was demonstrated between the uterus 
and bladder by transabdominal ultrasound (Fig. 3).
Of the 25 patients who received preventive UAE combined 
with MTX, there were no reports of irregular menstrual or 
serious adverse effects. Two patients developed postoperative 
fever but responded to anti-infective treatment administered at 
the hospital. Of the 25 patients, 12 had laparoscopy-guided curet-
tage and 13 had ultrasound-guided curettage. Of the patients 
who received laparoscopy-guided curettage, three patients 
chose the surgical option due to a desire for tube ligation. During 
follow up, no serious adverse effects were observed in these 
patients. However, serum β-HCG levels decreased more rapidly 
with ultrasound-guided curettage than with laparoscopy-guided 
Figure 2. Highly selective uterine artery angiograms. A 30-year-old woman with a history of one caesarean delivery having CSP at 6 weeks underwent 
preventive UAE. (A-G) Before UAE, selective uterine artery angiograms demonstrated enlarged and tortuous uterine arteries, with a hypervascular region 
overlying the lower uterine segment corresponding to the CSP region. (H and I) CSP image disappeared after an arterial occlusion was successfully achieved. 
CSP, caesarean scar pregnancy; UAE, uterine artery embolization.
Table II. A comparison of the different types of clinical cases.
Clinical Vaginal Abdominal Vaginal bleeding  Massive bleeding
presentation bleeding pain abdominal pain Asymptomatic after curettage
Case 11 1 5 8 5
Percentage 36.67% 3.33% 16.67% 26.67% 16.67%
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curettage. The decreased rate was 84.3±10.5 and 76.3±15.23%, 
respectively (Table III). In the patients undergoing laparoscopy 
and ultrasound-guided curettage, the serum β-HCG levels 
returned to normal after 25 and 34 days. The mean curettage 
time was 15±5.3 min and mean blood loss was 16±3.8 ml. 
Ultrasound examination was performed prior to discharge 
from the hospital to ensure that the caesarean scar had disap-
peared, and that no abnormal ultrasound findings were present. 
Follow-up interviews indicated that a normal menstrual cycle 
had returned 36.9±2.9 days postoperatively, with no reports of 
abnormal vaginal bleeding. None of the patients had normal 
intrauterine pregnancies during the follow-up period.
Discussion
CSP is a rare form of ectopic pregnancy. The etiology of 
CSP is unclear, but it is generally thought that CSP occurs 
when a blastocyst is implanted on fibrous scar tissue within a 
wedge-shaped myometrial defect in the anterior lower uterine 
segment at the site of a prior caesarean scar (12,13). The patho-
logical examination of excised CSP alone and in hysterectomy 
specimens demonstrated clusters of trophoblast cells as well as 
scattered syncytiotrophoblast cells invading the myometrium 
through a microscopic dehiscent tract created by a previous 
caesarean section procedure or other uterine surgery (12,13).
CSP can present at any time from implantation to term 
but has been reported to present more commonly in the first 
trimester. The common presenting symptoms are vaginal 
bleeding and abdominal pain, but at least one-third of patients 
are asymptomatic (6,14). The results of the present study indi-
cate one-fourth of patients. In the present study, five patients 
were misdiagnosed for having an intrauterine pregnancy and 
had uncontrolled massive hemorrhage after uterine curettage. 
Therefore, true diagnosis was crucial as a large number of 
complications caused by misdiagnosis may lead to inappro-
priate interventions. TVS was the reference standard for the 
diagnosis of CSP in the first trimester with a reported 86.4% 
sensitivity (12,14). Maymon et al (15) recommended using 
combined TVS and transabdominal sonography (TAS) with a 
full bladder. Thus a ‘panoramic view’ of the uterus is provided 
with accurate measurement of the distance between the gesta-
tional sac and bladder (15). In the present study, all 30 patients 
were diagnosed via a combination of TVS and TAS.
Two different types of CSP have been proposed (16). The 
first type is an implantation on the prior scar with progres-
sion towards the cervico-isthmic space or the uterine cavity. 
  A   B
  C   D
Figure 3. Dissection of uterus with CSP after hysterectomy. A 42-year-old woman with a history of one caesarean delivery had CSP for 8 weeks. She had 
uncontrolled haemorrhage due to CSP uterus rupture. (A) Whole uterus, (B) the gestational sac implanted into the caesarean scar myometrium, (C) chorionic 
villi from pregnancy at the caesarean scar, and (D) the sagittal angle of the cavity with respect to the scar tissue. CSP, caesarean scar pregnancy.
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Such a pregnancy may progress to viability with the risk of 
massive haemorrhage. The second type is a deep implantation 
into the caesarean scar defect growing towards the bladder and 
abdominal cavity and more prone to scar rupture (11,12).
Successful births have been described with the appropriate 
management, but the prognosis for an uneventful term preg-
nancy is poor. The hysterectomy rate in these cases is 71% 
because of the increased risk of placental previa/accreta and 
massive hemorrhage (12-17). Termination of the diagnosed 
cases by surgical or medical means may improve the outcomes 
by allowing preservation of the uterus and future fertility. It 
is anticipated that delay in treatment of scar pregnancies can 
lead to uterine rupture, hysterectomy and significant maternal 
morbidity (11,18). Various medical and surgical treatments 
have been attempted, however, there is no consensus on the 
optimal mode of treatment (19). Many medical and surgical 
approaches have been attempted with the aim of eliminating 
the gestational sac and preserving fertility, including systemic 
MTX or local injection into the gestation sac of MTX, potas-
sium chloride, hyperosmolar glucose or prostaglandins. The 
surgical methods included dilatation and curettage, UAE, 
hysteroscopic resection, laparoscopic resection or even hyster-
ectomy. Local, systemic and combined treatments with MTX 
have been described. However, fibrous tissue within the scar 
around the gestational sac can delay systemic MTX absorp-
tion into the sac (20). Local injection of embryocides under 
sonographic guidance may decrease the need of additional 
interventions compared to systemic MTX (11,12,14). However, 
close monitoring of the patient after intervention is required as 
hemorrhage may still occur. Therefore, bilateral UAE should 
be considered (13,15).
Surgical management with laparoscopy or laparotomy with 
excision of the pregnancy may be optima for women who do 
not respond to conservative medical treatments or are late to 
present for medical attention (19). However, surgery carries the 
risk of postoperative adhesions that may impair future fertility, 
increased size of surgical wounds, a longer hospital stay and 
recovery and possibly an increased risk of future placental 
previa/accreta (8,12,19). Dilation and curettage should not be 
considered as the first choice of therapy. This is because the 
majority of the villi are implanted in the myometrium and 
it seems unlikely that the gestational sac can be expelled by 
curettage without perforating the uterine wall or damaging 
the urinary bladder and may also cause life-threatening 
haemorrhage (8,12). Isolated suction curettage was used as the 
initial treatment on five of our patients. Four patients suffered 
life-threatening haemorrhage and one patient suffered uterine 
damage that finally led to hysterectomy. Previous findings 
Table III. A comparison of operative outcomes between laparoscopy-guided curettage and ultrasound-guided curettage.
  No. of Apart time of   Rate of
 No. of previous previous previous caesarean Blood loss Menstrual cycle serum β-HCG
 caesarean sections abortion section (years) volume (ml) recovery (days) reduction (%)a
Ultrasound-guided 1.14±0.3 1.86±1.03 3.71±3.36 17.50±4.16 37.14±3.79 88.43±10.50
curettage
Laparoscopy-guided 1.09±0.30 2.82±1.83 4.01±2.59 15.91±3.36 36.64±1.36 76.31±15.23
curettage
P-value 0.70 0.14 0.80 0.83 0.43 0.04
aThe reduction rate of serum HCG = preoperative serum HCG - postoperative serum HCG (three days after operation)/preoperative serum 
HCG. HCG, human chorionic gonadotropin.
Figure 5. Laparoscopic image of CSP showing the uterine segment with some 
large adhesions together with the surrounding tissues and caesarean scars 
from a patient with CSP. CSP, caesarean scar pregnancy.
Figure 4. Laparoscopic image of CSP showing a topical purple bulge in the 
lower segment over the caesarean scar from a patient with CSP. CSP, cae-
sarean scar pregnancy.
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suggest that selective UAE can temporarily block uterine 
perfusion and minimize hemorrhage and they have used this 
technique before or after curettage (21).
UAE treatment of CSP was first reported in 1999 and 
has been used widely to control haemorrhage and preserve 
the uterus (22,23). However, isolated UAE without elimi-
nating the gestational sac results in the gradual decrease of 
serum β-HCG levels and irregular menstrual bleeding (7,12). 
Therefore, uterine curettage should be performed after UAE. 
Gelfoam appears to promote clotting via physical effects by 
supporting thrombus development. Vascular occlusion with 
gelfoam causes acute necrotizing arteritis. This inflamma-
tory process eventually leads to breakdown of the gelfoam 
within 1-3 weeks after embolization, with subsequent vascular 
recanalization (24). Because of its temporary nature, uterine 
curettage should be carried out as soon as possible. In 
published studies, uterine curettage was usually carried out 
within 24-72 h after UAE (20). In accordance with our study, 
the results demonstrated that UAE followed by uterine curet-
tage may be an effective and safe treatment for CSP. In the 
pathological sample of CSP, trophoblast cells were found to 
have invaded the myometrium, adhered, implanted and even 
penetrated the myometrium (13). For this reason, 50 mg of 
MTX was given by infusing the arterial catheter to manage 
the possibility of residual villi in the scar tissue. Previous 
studies reported that MTX alone followed by suction curettage 
requires more hospitalization time and causes greater bleeding 
volumes compared with UAE (9). Therefore, curettage after 
UAE combined with MTX (50 mg) is a safe and effective 
means of treating CSP.
Of note, suction curettage may also be used to treat CSP, 
unlike ordinary curettage, because ultrasonography of CSP 
displays a thinned or absent myometrium between the gesta-
tional sac and bladder (<5 mm in two-thirds of cases). Thus, 
careful monitoring of curettage is necessary to avoid damaging 
the uterus. Compared with laparoscopy-guided and ultra-
sound-guided curettage, vaginal bleeding and length of stay 
in hospital showed no significant difference, although serum 
β-HCG levels decreased more rapidly with ultrasound-guided 
curettage than with laparoscopy-guided curettage. The rate of 
decline was 84.3±5.5 and 76.3±10.2%, respectively. The reason 
may be that the sonogram shows more clearly the location of 
the gestational sac and thickness of the myometrium between 
the gestational sac and bladder. When curettage is monitored 
by ultrasound, the operators can remove the ectopic sac under 
direct vision and have clear views of the endometrium and 
myometrium. The advantage of laparoscopy-guided curettage 
is observing the appearance of the uterus under direct vision 
during exploration. The topical purple bulge was usually 
seen in the lower segment over the caesarean scar. The blood 
vessels show hyperplasia in the same area (Fig. 4). However, 
in the current study, eight of the laparoscopy-guided cases 
showed the uterine segment had some heavy adhesions with 
the surrounding tissues and caesarean scars were not easy to 
expose (Fig. 5).
Separating the adhesion may increase the risk of tissue 
damage. Furthermore, laparoscopic surgery may require 
anaesthesia and increase the costs and risk of surgery. 
Therefore, we considered whether ultrasound-guided curet-
tage may be appropriate in women who are hemodynamically 
stable with an unruptured CSP of a myometrial thickness 
of >2 mm. Medical treatment including local, systemic and 
combined treatment with MTX may be appropriate in women 
with an unruptured CSP of <8 weeks' gestation and a myome-
trial thickness of <2 mm (6,12).
There is no consensus on time period required for the 
following pregnancy or the risk of future pregnancies. The 
present study results indicated that, none of the patients had 
normal intrauterine pregnancies during the follow-up period, 
although the patients were followed up for only one year and 
the long-term consequences of the treatment are unknown. A 
recent study of 24 women successfully treated for prior CSP 
without surgical correction of the scar reported favourable 
reproductive outcomes and a recurrence rate of only 5% (17). 
It showed that 88% of woman conceived naturally, and 95% of 
the pregnancies were intrauterine while 65% appeared normal. 
Thirty-five percent ended in spontaneous abortion. Findings 
of that study showed that, fertility was successfully preserved 
in the women who opted for first-trimester termination of 
CSP (17). However, the findings require further validation in a 
larger group of cases.
In conclusion, CSP is an uncommon but dangerous occur-
rence because of the increased risk of uterine rupture and 
massive haemorrhage. The precise localization of early preg-
nancies by sonography and early recognition of the typical 
sonographic findings are critical. In diagnosing CSP, TVS 
and TAS should be used in combination to obtain an accurate 
diagnosis. Based on the present findings  it may be concluded 
that UAE combined with MTX followed by ultrasound-guided 
curettage may be an effective and safe treatment for CSP. 
More importantly, emergency UAE should be recommended 
as the first choice to treat uncontrollable massive haemorrhage 
of CSP and preserve the uterus and future fertility.
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